The company will now conclude enrollment for the study while maintaining oversight of current participants, following the established trial protocol. This clinical milestone paves the way for a supplemental biologic license application, which Humacyte expects to submit to the Food and Drug Administration during the second half of this year. The target demographic includes adult patients facing a high risk of arteriovenous fistula maturation failure.
In section Market Quotes
Humacyte Clears Phase 3 Hurdle for Bioengineered Vascular Implant
With an average of 91 additional catheter-free days compared to standard care, Humacyte’s acellular tissue-engineered vessel has reached its primary endpoint in a Phase 3 trial. The results, drawn from the initial 80 patients, mark a potential shift in treatment for those suffering from end-stage kidney disease.
To support the commercial rollout of its product, branded as Symvess, and to bolster its broader research pipeline, Humacyte has launched an underwritten public offering of its common stock. While the specific volume of shares remains undisclosed, the company has granted underwriters a 30-day window to purchase an additional 15% of the offering to cover potential excess demand.
Comments (0)
No comments yet. Be the first!